Loading...
•
Dec 31, 2020
Ardelyx Q4 2020 Earnings Report
Ardelyx reported fourth quarter and full year 2020 financial results, highlighting the company's readiness for the potential launch of tenapanor.
Key Takeaways
Ardelyx reported total revenues of $1.809 million for the fourth quarter of 2020 and a net loss of $28.876 million. The company's cash, cash equivalents and investments are expected to fund operations into the second half of 2022.
Submitted NDA for tenapanor for hyperphosphatemia with PDUFA date of April 29, 2021.
Presented data from Phase 1 clinical study with RDX013, planning Phase 2 study in 2021.
Enhanced commercial capabilities with key leadership appointments.
Launched “Can We Do Better?” Disease Awareness Campaign.
Forward Guidance
Ardelyx expects that its cash, cash equivalents and investments will be sufficient to fund the company’s operations into the second half of 2022 based on its current operating plans.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...